Admedus acquires manufacturing facility from Genzyme Australasia

Healthcare group Admedus (formerly Allied Healthcare) has signed a share purchase agreement to acquire an established manufacturing site from Genzyme Australasia, a Sanofi company. Admedus purchased the site to facilitate scaled-up production of its regenerative tissue product CardioCel, used for the repair and reconstruction of congenital heart defects, and to meet future growth in demand for the product.

The site is located in Malaga, WA, and is expected to provide fully operational infrastructure enabling the company to service the global market for CardioCel. It will also provide additional facilities to support the development and commercial manufacture of other regenerative tissue products currently in the Admedus pipeline.

The leased site is fully fitted with the required cleanroom facilities and supporting infrastructure for Admedus to manufacture CardioCel. The purchase price of the manufacturing facility includes all existing equipment at the site, and the acquisition also provides access to highly skilled staff to support both manufacturing requirements and new product development.

Admedus CEO Lee Rodne said the acquisition “gives us immediate access to a fully functional facility, the necessary equipment and trained, experienced staff. As a result, this will accelerate our ability to increase the manufacturing of CardioCel as market demand grows.”

The transaction is expected to be completed as of 31 December.